Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors

• Published in: Supportive care in cancer Vol. 30; no. 3; pp. 2307 - 2315
• Main Authors: van Elst, Jip M., IJzerman, Nikki S., Mathijssen, Ron H. J., Steeghs, Neeltje, Reyners, Anna K. L., de Haan, Jacco J.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2022; Springer; Springer Nature B.V
• Subjects: Cancer; Care and treatment; Chemosensory perception; Chemotherapy; Drug therapy; Gastric cancer; Gastrointestinal cancer; Gastrointestinal Neoplasms - drug therapy; Gastrointestinal Stromal Tumors - drug therapy; Humans; Inhibitor drugs; Medicine; Medicine & Public Health; Nursing; Nursing Research; Oncology; Original Article; Pain Medicine; Phenols; Protein Kinase Inhibitors - adverse effects; Quality of Life; Questionnaires; Rehabilitation Medicine; Smell; Targeted cancer therapy; Taste; Tyrosine; Taste disturbances; Imatinib; Tyrosine-kinase inhibitors; Smell disturbances; Gastrointestinal stromal tumor
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-021-06658-z

Context Taste, smell, and mouthfeel disturbances are underrated and underreported, but important side effects of anti-cancer medication. These symptoms are associated with a lower quality of life (QoL). The prevalence and the impact of taste, smell, and mouthfeel disturbances on daily life in patients with a gastrointestinal stromal tumor (GIST) are largely unknown. Objectives This exploratory study assessed the prevalence and type of taste, smell, and mouthfeel disturbances and their impact on daily life and QoL in patients with a GIST treated with a tyrosine-kinase inhibitor (TKI). Methods Patients currently treated with TKIs for GIST completed a standardized questionnaire. The questionnaire addressed changes in taste, smell, and mouthfeel and, if changes occurred, impact on daily life and QoL. Statistics are descriptive. Results A total of 65 GIST patients on TKI treatment completed the questionnaire. Of these patients, 79%, 12%, and 9% currently used imatinib, sunitinib, and regorafenib respectively. Taste, smell, and mouthfeel disturbances were reported by 25 (38%), 15 (23%), and 36 (55%) patients respectively. Salty and sweet tastes were mostly affected, respectively in 14 and 13 patients. A dry mouth was experienced by 29 (45%) patients. Taste disturbances were more often reported to have impact on daily life and QoL (80% and 60%) than smell (47% and 31%) and mouthfeel disturbances (47% and 30%). Conclusion Taste, smell, and mouthfeel disturbances are frequent side effects of TKIs in GIST patients. Daily life and QoL are affected in a considerable number of those patients. Trial registration ClinicalTrials.gov Identifier: NL7827 (2019–06-25).